Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7166909 | 0.78 | HRH3 (0.40) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| Ammonia Solution, Strong SCHEMBL29032591 | 0.77 | HRH3 (0.39) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL14639772 | 0.75 | GABRA1 (0.32) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| Formamide SCHEMBL28844183 | 0.75 | HRH3 (0.36) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL1436027 | 0.72 | HRH3 (0.40) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL26029113 | 0.72 | ALDH1A1 (0.42) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL1646402 | 0.72 | ALDH1A1 (0.45) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL321823 | 0.72 | KDM4E (0.40) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL25169306 | 0.72 | KDM4E (0.47) | KDM4EALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL7167022 | 0.72 | TAAR1 (0.40) | KDM4EALDH1A1MAPTL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776107-B2 | Aminoindolizines, dyeing composition comprising at least one aminoindolizine, methods and uses thereof | L'OREAL S.A. (FR) | 2010-08-17 | — | — | US | disclosed |
| US-7776107-B2 | Aminoindolizines, dyeing composition comprising at least one aminoindolizine, methods and uses thereof | L'OREAL S.A. (FR) | 2010-08-17 | — | — | US | disclosed |
| US-7776107-B2 | Aminoindolizines, dyeing composition comprising at least one aminoindolizine, methods and uses thereof | L'OREAL S.A. (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090235467-A1 | NEW AMINOINDOLIZINES, DYEING COMPOSITION COMPRISING AT LEAST ONE AMINOINDOLIZINE, METHODS AND USES THEREOF | L'OREAL S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20090235467-A1 | NEW AMINOINDOLIZINES, DYEING COMPOSITION COMPRISING AT LEAST ONE AMINOINDOLIZINE, METHODS AND USES THEREOF | L'OREAL S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-20090235467-A1 | NEW AMINOINDOLIZINES, DYEING COMPOSITION COMPRISING AT LEAST ONE AMINOINDOLIZINE, METHODS AND USES THEREOF | L'OREAL S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| EP-2093226-A1 | New aminoindolizines, tinctorial composition comprising an aminoindolizine, methods and uses | L'Oreal (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-2093226-A1 | New aminoindolizines, tinctorial composition comprising an aminoindolizine, methods and uses | L'Oreal (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-1495023-B1 | NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-09-07 | — | — | EP | disclosed |
| EP-1495023-A1 | NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084956-A1 | NOVEL 1,2,3-SUBSTITUTED INDOLIZINE DERIVATIVES, INHIBITORS OF FGFS, METHOD FOR MAKING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090235467-A1 | NEW AMINOINDOLIZINES, DYEING COMPOSITION COMPRISING AT LEAST ONE AMINOINDOLIZINE, METHODS AND USES THEREOF | KRT18, AADAT, ALAD | KDM4E 977/4885ALDH1A1 723/4885MAPT 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.